NUVB
Nuvation Bio Inc.Company Information
- Company Name
- Nuvation Bio Inc.
- CIK
- CIK0001811063
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- NUVB: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- NUVB
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-09
- Last sale
- 2026-08-19
- Shares purchased (TTM)
- 25,000
- Shares sold (TTM)
- 1,486,469
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 227,660,003
- Shares outstanding
- 348,770,000
- Ownership
- 65.28%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 9.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 259 | 125 | 164 | 99 | 248 | 48 | 36 | 30 | 34 | 35 | 43 | 24 | ||||||
| Accounts Receivable Net | 28 | 23 | 16 | 8 | 3 | 0 | 13 | 0 | 0 | - | 0 | - | ||||||
| Inventory Net | 20 | 16 | 11 | 6 | 1 | 0 | 0 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 14 | 16 | 12 | 9 | 8 | 8 | 7 | 12 | 6 | 7 | 2 | 3 | ||||||
| Marketable Securities Current | 402 | 408 | 365 | 450 | 360 | 414 | 467 | 519 | 543 | 562 | 569 | 595 | ||||||
| Assets Current | 726 | 592 | 572 | 578 | 623 | 476 | 526 | 565 | 587 | 608 | 616 | 625 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finite Lived Intangible Assets Net | 10 | 11 | 11 | 12 | 12 | 4 | 5 | 3 | 3 | - | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 3 | 4 | 4 | 4 | 5 | 5 | 2 | 2 | 3 | 3 | 4 | 4 | ||||||
| Other Assets Noncurrent | 4 | 4 | 8 | 7 | 7 | 7 | 7 | 0 | 1 | 1 | 1 | 1 | ||||||
| Assets | 745 | 610 | 595 | 602 | 647 | 492 | 541 | 572 | 595 | 613 | 621 | 631 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 12 | 22 | 9 | 15 | 22 | 11 | 6 | 12 | 5 | 2 | 2 | 2 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Contract With Customer Liability Current | 9 | 9 | 8 | 7 | 10 | 11 | 11 | 13 | 12 | - | 0 | - | ||||||
| Short Term Borrowings | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 8 | 12 | - | 0 | - | ||||||
| Accrued Liabilities Current | 45 | 33 | 45 | 33 | 24 | 24 | 33 | 24 | 20 | 11 | 10 | 12 | ||||||
| Liabilities Current | 87 | 80 | 82 | 68 | 66 | 53 | 58 | 59 | 51 | 16 | 14 | 16 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | 14 | 16 | 8 | 9 | - | 0 | - | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 3 | 3 | 3 | 4 | 1 | 1 | 1 | 2 | 2 | 3 | ||||||
| Deferred Revenue Noncurrent | 151 | 152 | 146 | 145 | 143 | - | 0 | - | - | - | - | - | ||||||
| Other Long Term Debt Noncurrent | 0 | 47 | 47 | 47 | 47 | - | 0 | - | - | - | - | - | ||||||
| Convertible Debt | 243 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 491 | 291 | 289 | 276 | 274 | 73 | 77 | 69 | 63 | 19 | 16 | 19 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | - | - | - | - | - | - | 275 | - | - | - | ||||||
| Common Stock Value | 1,429 | 1,431 | 1,421 | 1,405 | 1,396 | 1,383 | 1,374 | 1,363 | 1,079 | 953 | 948 | 944 | ||||||
| Retained Earnings Accumulated Deficit | -1,173 | -1,110 | -1,115 | -1,079 | -1,023 | -964 | -911 | -861 | -820 | -358 | -343 | -329 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -3 | -2 | -0 | -0 | -0 | 1 | 1 | 1 | -1 | -1 | 0 | -3 | ||||||
| Stockholders Equity | 254 | 320 | 306 | 326 | 373 | 419 | 464 | 503 | 257 | 594 | 605 | 612 | ||||||
| Liabilities And Stockholders Equity | 745 | 610 | 595 | 602 | 647 | 492 | 541 | 572 | 595 | 613 | 621 | 631 | ||||||
| Deferred Finance Costs Net | 3 | 3 | 3 | 3 | 3 | - | 0 | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,060 | 1,060 | 1,060 | 1,060 | 1,060 | 1,060 | 347 | - | - | - | - | - | ||||||
| Common Stock Shares Issued | 350 | 348 | 338 | 343 | 342 | 340 | 338 | 336 | 249 | 219 | 219 | 219 | ||||||
| Shares Outstanding | 347 | 347 | 338 | 338 | 338 | 338 | 338 | 336 | 249 | 219 | 219 | 219 | ||||||
| Allowance For Doubtful Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNuvation Bio Inc. (NUVB) — SEC Financial Statements & Analysis
Nuvation Bio Inc. (NUVB) is a pharmaceutical preparations company, incorporated in DE. Nuvation Bio Inc. trades on NYSE as: NUVB. Nuvation Bio Inc. (NUVB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Nuvation Bio Inc. carries a market cap of $1.98B, a P/E ratio of -13.22x, a P/B ratio of 7.80x, a P/S ratio of 11.66x, an enterprise value of $1.97B, and an EV/EBITDA multiple of -14.55x. On profitability, it posts a gross margin of 54.26%, an operating margin of -81.00%, a net margin of -88.19%, a Return on Equity (ROE) of -47.81%, a Return on Assets (ROA) of -21.53%, and a Return on Invested Capital (ROIC) of -72.82%. Per share, it reports EPS of $-0.43, diluted EPS of $-0.43, free cash flow per share of $-0.37, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 1083.56% year-over-year, net income growth of -26.16% year-over-year, and EPS growth of -27.86% year-over-year. On the balance sheet, it maintains a current ratio of 8.37x, a quick ratio of 7.98x, working capital of $639.68M, a debt-to-equity ratio of 1.93x, a debt ratio of 0.66, an interest coverage ratio of -5.16x, free cash flow of $-128.52M (TTM), and net debt of $-10.09M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.98B
- P/E TTM
- -13.22x
- EPS TTM
- $-0.43
- P/B TTM
- 7.80x
- ROE TTM
- -47.81%
- ROA TTM
- -21.53%
- Debt To Equity
- 1.93x
- Free Cash Flow TTM
- $-128.52M
- Net Revenue TTM Growth 1Y
- 1083.56%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Nuvation Bio Inc. in?
Nuvation Bio Inc. (NUVB) operates in the Pharmaceutical Preparations industry.
What exchange does NUVB trade on?
Nuvation Bio Inc. (NUVB) trades on the NYSE.
Where is Nuvation Bio Inc. incorporated?
Nuvation Bio Inc. is incorporated in DE.
When was Nuvation Bio Inc. (NUVB)'s most recent SEC filing?
Nuvation Bio Inc. (NUVB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is NUVB's market cap?
Nuvation Bio Inc. (NUVB) has a market capitalization of $1.98B as of 2026-06-30.
What is NUVB's EPS (earnings per share)?
Nuvation Bio Inc. (NUVB)'s trailing twelve month EPS is $-0.43 as of 2026-06-30.
What is NUVB's ROE (return on equity)?
Nuvation Bio Inc. (NUVB)'s trailing twelve month Return on Equity (ROE) is -47.81% as of 2026-06-30.
What is NUVB's ROA (return on assets)?
Nuvation Bio Inc. (NUVB)'s trailing twelve month Return on Assets (ROA) is -21.53% as of 2026-06-30.
What is NUVB's ROIC (return on invested capital)?
Nuvation Bio Inc. (NUVB)'s trailing twelve month Return on Invested Capital (ROIC) is -72.82% as of 2026-06-30.
What is NUVB's EV/EBITDA?
Nuvation Bio Inc. (NUVB)'s trailing twelve month EV/EBITDA is -14.55x as of 2026-06-30.